Silence Therapeutics shores up US patent estate

03:19 EDT 31 Jul 2017 | Proactive Investors

Silence Therapeutics PLC (LON:SLN) has broadened its patent estate in the US with the grant of further protection over its chemical modification technology. It is part of an ongoing process as it eyes companies with drugs in clinical trials that may be piggybacking on its intellectual property. “In allowing this additional patent application for grant, the US Patent and Trade Mark Office has continued to uphold the validity of our expanding US patent estate,” said chief executive Ali Mortazavi.  “We continue to believe that several third party late‐stage clinical RNAi candidates require licences under our patent portfolio.” The company is a pioneer in RNA interference (RNAi). This is the cellular process of silencing unwanted or harmful genes.

Original Article: Silence Therapeutics shores up US patent estate


More From BioPortfolio on "Silence Therapeutics shores up US patent estate"

Quick Search

Relevant Topic

Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...